Post-trial follow-up | Microbiome therapeutic SER-109 through 24 weeks for recurrent Clostridioides difficile infection.

Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial – JAMA (free for a limited period)

Original Study: RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).

Commentary on Twitter

SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, durably reduced recurrent Clostridioides difficile infection rates and was well-tolerated through 24 weeks in patients with prevalent comorbidities. https://t.co/abayN0iJ5z

— JAMA (@JAMA_current) October 19, 2022